MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
POSTION SUMMARY
Aa core member of the International Leadership, this position plays a key strategic and operational role within International Region. The Vice President Commercial Operations will lead International Regions in all aspects of commercialization and business performance: strategy, brand planning process, tactical execution, launch readiness and execution, operational excellence and delivering on established KPIs. This position will be key in driving the commercialization of the company’s existing portfolio and upcoming launches. The individual will work closely with cross-functional team across the organization.
JOB FUNCTIONS/RESPONSIBILITIES
- Develop and execute the International commercial strategy in alignment with global priorities.
- Lead end-to-end launch excellence across International markets, including readiness planning, resource allocation, market sequencing, and post-launch performance optimization.
- Help build the Mirum culture by serving as an effective bridge between International and US teams.
- Ensure execution of all operational business activities to maximize patient access and commercial impact.
- Lead regional marketing and commercial operations team
- Ensure the critical linkage across commercial, medical affairs, regulatory affairs, market access, finances, compliance and to support all partners in executing best in-class operational activities.
- Continuously assess productivity and efficiency of commercial organization, lead commercial operating model strategic thinking across markets – directly or in close collaboration with partners.
- Drive initiatives to prepare for further sustainable growth in International: commercial KPIs benchmarking, business plan, sales plans and forecasting models, marketing tactics, etc.
- Prioritize key strategic initiatives in collaboration with global / International leadership team and other stakeholders to build optimal organization that enables long term sustainable growth.
- Partner for all global Business development opportunities assessment in the region.
- Ensure adherence to all relevant legal, regulatory and compliance requirements, corporate policies and procedures.
QUALIFICATIONS
Education/Experience:
- Extensive expertise in the pharmaceutical/biotech commercial operations, in multiple healthcare systems, especially in European markets.
- Proven successful experience in operational commercial role at regional as well as local country level.
- Hands-on involvement in the development of commercial strategy, etc.
- Rare or ultra-rare disease experience preferred.
- Good understanding of commercial, access and regulatory process.
- Undergraduate degree required, MBA and/or relevant postgraduate qualifications preferred.
- 15+ years experience in life sciences, start up, biotech or pharma industry, in marketing/commercial functions.
- Eligibility to work in Switzerland (valid Swiss work permit) is required.
Knowledge, Skills and Abilities:
- Strong strategic thinking and capacity to execute strategy in a variety of business environment in International region.
- Able to drive initiatives and lead new projects in a lean organization by working cross functionally and using key stakeholders’ areas of expertise.
- Enjoy building and creating and is a self-starter.
- Highly organized and comfortable managing multiple work streams at once.
- Exceptional communication and interpersonal skills.
- Great attention to detail and self-motivation.
- Willingness to travel internationally
#LI-HYBRID
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.
Mirum Pharmaceuticals Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Mirum Pharmaceuticals and has not been reviewed or approved by Mirum Pharmaceuticals.
-
Equity Value & Accessibility — Equity grants to new hires and an employee stock purchase plan make ownership more accessible and can boost total rewards when performance is strong. Public disclosures highlight frequent option/RSU inducements.
-
Healthcare Strength — Comprehensive medical, dental, and vision coverage is employer-paid for employees, with added life, disability, and EAP support. This combination reduces financial burden and enhances overall wellbeing.
-
Leave & Time Off Breadth — A broad time-off program includes multiple paid company holidays, a year-end shutdown, accrued vacation, and paid parental leave. This breadth provides additional rest periods beyond standard vacation.
Mirum Pharmaceuticals Insights
Similar Jobs
What We Do
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome. Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome. Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.
